AAPL 167.04 -0.5714% MSFT 404.33 -1.8235% GOOG 157.46 0.3697% GOOGL 155.9725 0.3232% AMZN 179.17 -1.1639% NVDA 846.71 0.7568% META 501.8 1.544% TSLA 149.9 -3.5703% TSM 132.27 -4.8623% LLY 745.95 -0.642% V 271.36 -0.4877% AVGO 1258.99 -1.8431% JPM 181.25 0.6497% UNH 493.18 2.9625% NVO 122.75 -1.4294% WMT 59.27 -0.637% LVMUY 170.18 -0.3338% XOM 118.47 -0.1349% LVMHF 854.0 -0.4662% MA 454.7 -1.1865%

Bionano Genomics Inc

Healthcare US BNGO

0.7872USD
-0.0286(3.51%)

Last update at 2024-04-18T20:10:00Z

Day Range

0.710.82
LowHigh

52 Week Range

1.1920.20
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -130.71200M -78.15200M -41.10635M -29.81507M -18.48088M
Minority interest - - - - -
Net income -132.59600M -72.43500M -41.13554M -29.83612M -18.49639M
Selling general administrative 88.60M 58.49M 31.07M 20.16M 14.22M
Selling and marketing expenses - - - - -
Gross profit 5.95M 3.87M 2.77M 3.36M 3.29M
Reconciled depreciation 9.84M 3.37M 1.48M 1.13M 1.32M
Ebit -131.69800M -77.10100M -40.03086M -27.00276M -22.41146M
Ebitda -130.41400M -76.92400M -38.55132M -25.87491M -21.09094M
Depreciation and amortization 1.28M 0.18M 1.48M 1.13M 1.32M
Non operating income net other -0.22300M -0.36000M -0.00694M -1.63292M 3.32M
Operating income -131.69800M -77.10100M -38.55132M -25.87491M -20.41509M
Other operating expenses 159.50M 95.08M 47.05M 36.00M 32.42M
Interest expense 0.30M 0.93M 2.52M 2.29M 1.38M
Tax provision 1.88M -5.71700M 0.03M 0.02M 0.02M
Interest income 1.51M 0.24M - 2.29M 1.38M
Net interest income 1.21M -0.69100M -2.51889M -2.28620M -1.38102M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.88M -5.71700M 0.03M 0.02M 0.02M
Total revenue 27.80M 17.98M 8.50M 10.13M 12.00M
Total operating expenses 137.64M 80.97M 41.32M 29.24M 23.70M
Cost of revenue 21.86M 14.11M 5.73M 6.77M 8.71M
Total other income expense net 0.99M -1.05100M -2.55503M -3.94016M 3.32M
Discontinued operations - - - - -
Net income from continuing ops -132.59600M -72.43500M -41.10635M -29.81507M -18.49639M
Net income applicable to common shares -132.59600M -72.43500M -41.10635M -29.81507M -18.49639M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 307.50M 377.10M 60.45M 30.21M 24.80M
Intangible assets 41.14M 26.84M 1.47M - -
Earning assets - - - - -
Other current assets 7.33M 4.48M 2.25M 1.17M 0.92M
Total liab 58.10M 39.98M 25.37M 26.64M 14.67M
Total stockholder equity 249.40M 337.12M 35.08M 3.61M 10.14M
Deferred long term liab 0.13M 0.15M 0.10M 0.18M 0.30M
Other current liab 19.93M 9.69M 5.60M 3.23M 2.90M
Common stock 0.03M 0.03M 0.02M 0.00343M 0.00100M
Capital stock 0.03M 0.03M 0.02M 0.00343M 0.00100M
Retained earnings -348.71500M -216.11900M -143.68385M -102.57750M -72.76243M
Other liab 13.10M 9.21M 0.10M 0.23M 1.11M
Good will 77.29M 56.16M 7.17M - -
Other assets 2.81M 0.75M 0.10M - -
Cash 5.09M 24.57M 38.45M 17.31M 16.52M
Cash and equivalents - - - - -
Total current liabilities 35.88M 21.84M 8.94M 26.30M 4.52M
Current deferred revenue 0.87M 0.68M 0.42M 0.36M 0.27M
Net debt 6.58M -13.87500M -22.12321M 2.71M -7.49336M
Short term debt 2.54M 1.77M 20.08M 20.02M -
Short long term debt - - - 20.08M -
Short long term debt total 11.67M 10.70M 16.33M 20.02M 9.03M
Other stockholder equity 599.21M 553.75M 178.75M 106.19M -24714.35986M
Property plant equipment 18.03M 10.32M 4.91M 1.95M 1.78M
Total current assets 157.30M 272.41M 46.79M 28.26M 23.03M
Long term investments - - - - -
Net tangible assets 172.11M 337.12M 26.43M 3.61M 10.14M
Short term investments 108.09M 226.04M - - -
Net receivables 7.02M 4.93M 2.78M 6.33M 4.51M
Long term debt - - 16.33M - 9.03M
Inventory 29.76M 12.39M 3.32M 3.44M 1.07M
Accounts payable 12.53M 9.70M 2.93M 2.70M 1.35M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.12400M -0.53900M - -6.27347M -5.16236M
Additional paid in capital - - - - -
Common stock total equity 0.03M 0.03M 0.02M 0.00343M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity -348.71500M -216.11900M -143.68385M -102.57750M -72.76243M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.81M 0.75M 0.10M 1.95M 1.78M
Deferred long term asset charges - - - - -
Non current assets total 150.20M 104.69M 13.66M 1.95M 1.78M
Capital lease obligations 11.67M 10.70M - - -
Long term debt total - - 16.33M - 9.03M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 116.69M -226.90900M -2.44995M -0.06106M -0.33172M
Change to liabilities 2.31M 10.74M -1.80931M 1.29M -1.20178M
Total cashflows from investing activities 82.77M -278.06200M -2.44995M -0.06106M -0.33172M
Net borrowings -0.03600M -15.00000M -4.72335M 9.82M 16.38M
Total cash from financing activities 23.01M 336.11M 61.90M 30.38M 35.78M
Change to operating activities -3.96100M 1.99M 0.48M -0.31896M -0.09539M
Net income -132.59600M -72.43500M -41.10635M -29.81507M -18.49639M
Change in cash -19.08000M -13.87800M 21.14M 0.79M 15.50M
Begin period cash flow 24.57M 38.45M 17.31M 16.52M 1.02M
End period cash flow 5.49M 24.57M 38.45M 17.31M 16.52M
Total cash from operating activities -124.81600M -71.92700M -38.31438M -29.52972M -19.94385M
Issuance of capital stock 23.13M 342.71M 39.93M 19.56M 19.39M
Depreciation 9.84M 3.37M 1.48M 1.13M 1.32M
Other cashflows from investing activities -33.13400M -50.51500M -2.44995M -0.60700M -0.60700M
Dividends paid - - - - -
Change to inventory -23.67600M -15.92800M -4.20128M -3.64102M -0.41898M
Change to account receivables -2.90000M -0.49300M 2.09M -2.37450M -0.90012M
Sale purchase of stock 22.89M 351.03M 66.59M 20.42M 19.39M
Other cashflows from financing activities -0.08500M 8.40M 29.23M 25.25M 23.83M
Change to netincome 25.21M 4.21M 4.75M 4.13M -0.69656M
Capital expenditures 3.30M 1.46M 4.66M 0.06M 0.33M
Change receivables -2.90000M -0.49300M 2.09M -2.37450M -0.90012M
Cash flows other operating -3.42600M -1.70400M -0.99919M -0.24505M 0.27M
Exchange rate changes - - - - -
Cash and cash equivalents changes -19.04200M -13.87800M 21.14M 0.79M 15.50M
Change in working capital -28.58800M -7.65200M -3.44017M -4.97207M -2.36887M
Stock based compensation 22.42M 9.72M 1.55M 1.35M 1.31M
Other non cash items 2.35M 0.85M 1.26M 0.88M 0.75M
Free cash flow -128.11800M -73.38700M -38.31438M -29.59078M -20.27556M

Fundamentals

  • Previous Close 0.82
  • Market Cap65.64M
  • Volume2356190
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-133.26900M
  • Revenue TTM33.61M
  • Revenue Per Share TTM1.06
  • Gross Profit TTM 5.95M
  • Diluted EPS TTM-7.17

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BNGO
Bionano Genomics Inc
-0.0286 3.51% 0.79 - - 1.87 0.53 0.28 -0.0438
ISRG
Intuitive Surgical Inc
-1.325 0.35% 372.85 76.39 50.76 16.72 9.14 16.12 52.74
ESLOY
Essilor International SA
1.85 1.73% 108.85 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme
1.63 0.76% 214.88 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company
0.94 0.40% 233.15 47.65 17.51 3.60 2.69 4.33 19.06

Reports Covered

Stock Research & News

Profile

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

Bionano Genomics Inc

9540 Towne Centre Drive, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Dr. Robert Erik Holmlin M.B.A., Ph.D. Pres, CEO, Sec. & Director 1968
Mr. Mark Oldakowski Chief Operating Officer 1974
Mr. Christopher P. Stewart Chief Financial Officer 1970
Mr. Mark Adamchak CPA VP of Accounting & Controller NA
Jonathan Dixon Global Head of Legal NA
Mr. Stanislas Marin M.B.A., M.S. Head of Global Sales NA
Ms. Helene Klein Chief People Officer NA
Dr. Alka Chaubey FACMG, Ph.D. Chief Medical Officer 1973
Dr. Soheil Shams Ph.D. CIO of Emeritus 1964
Ms. Donna Polizio Global Head of Market Access NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).